Verastem reports 31% ORR with avutometinib/defactinib in RAMP 201; NDA submission ongoing

Verastem, Inc.

Confirmed ORR of 31% overall (44% KRAS mutant, 17% KRAS wild type) by BICR.
Median duration of response 31.1 months; median PFS 12.9 months overall.
Discontinuation rate due to AEs was 10%; safety manageable with dose modifications.
Low-dose regimen (1.6 mg avutometinib) suboptimal; 22% progressed within 4 months vs 12% at 3.2 mg.
Rolling NDA submission to FDA for avutometinib+defactinib in recurrent LGSOC is underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.